Sutro Biopharma, Inc.: Form 10-K for the period ended Dec 31, 2020
Filed with the SEC on Mar 18, 2021 and accepted by EDGAR at Mar 17, 2021, 18:52 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-10-01 to 2020-12-31 | $8.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2020-01-01 to 2020-12-31 | $42.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2020-01-01 to 2020-12-31 | $77.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$71.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $100.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-10-01 to 2020-12-31 | −$59.5m | us-gaap:NetIncomeLoss |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$32.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-10-01 to 2020-12-31 | −$1.48 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-10-01 to 2020-12-31 | −$1.48 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$67.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2020-12-31 | $206.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $378.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $394.1m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $29.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $62.1m | us-gaap:Liabilities |
| Long-term debt | At period end2020-12-31 | $24.5m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2020-12-31 | $332.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-21-013945. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.